FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

No FDA Product Submissions with Fees Until Budget Passes

[ Price : $8.95]

During the current budget impasse on Capitol Hill and partial government shutdown, FDA says it cannot accept medical product submi...

IDE Early Feasibility Study Guidance

[ Price : $8.95]

FDA issues a guidance on developing and reviewing IDE applications for early feasibility studies of significant risk devices.

Comments Extended on Product Application Data Availability

[ Price : $8.95]

Federal Register Notice: FDA extends the comment period on a 6/4 Federal Register notice on the proposed availability of de-identi...

Comments Sought on IRB Recordkeeping

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on recordkeeping requirements for institutional review boards.

Comments Sought on Biologics Communication Studies

[ Price : $8.95]

Federal Register Notice: FDA seeks comments on a proposed collection of information on studies about biological product communicat...

Like the Phoenix, Pay-for Device Inspections Rise from the Ashes?

[ Price : $8.95]

Former FDA district director John Scharmann says CDRHs plan to pilot pay-for third-party inspections in January is likely to be as...

Vertex sNDA for Kalydeco Expanded Indication

[ Price : $8.95]

Vertex Pharmaceuticals files a supplemental NDA for Kalydeco (ivacaftor) monotherapy for people with cystic fibrosis aged six and ...

CDER Guidance on ANDA Refuse-to-Receive Criteria

[ Price : $8.95]

CDER releases a draft guidance on ANDA Submissions ― Refuse-to-Receive Standards that describes what should be included in a...

FDA to Retain 8,000 (55%) of its Staff Under Shutdown Plan

[ Price : $8.95]

Absent some miraculous compromise on Capitol Hill, it appears a government shutdown affecting almost half of FDA personnel is like...

FDA Accelerated Approval for Genentechs Perjeta

[ Price : $8.95]

FDA grants accelerated approval to Genentech for Perjeta (pertuzumab) and its use as part of a complete treatment regimen for pati...